Jefferies Financial Group Inc. Reduces Holdings in uniQure N.V. $QURE

Key Points

• Jefferies cut its stake in uniQure by 95.7% in Q3, selling 2,005,389 shares and leaving it with 90,542 shares worth about $5.29 million (≈0.17% ownership).
• Corporate insiders sold 81,399 shares (~$1.53M) in the last quarter (insiders now own 4.79%) while institutional investors hold roughly 78.83% of the stock.
• The outlook is mixed: uniQure beat EPS and revenue estimates but remains deeply unprofitable, analysts are split with some price‑target upgrades, and ongoing regulatory uncertainty plus multiple class‑action filings over AMT‑130 create material legal and clinical risk.

Jefferies Financial Group Inc. decreased its position in shares of uniQure N.V. (NASDAQ:QURE - Free Report) by 95.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 90,542 shares of the biotechnology company's stock after selling 2,005,389 shares during the quarter. Jefferies Financial Group Inc. owned approximately 0.17% of uniQure worth $5,285,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Private Trust Co. NA purchased a new stake in uniQure during the third quarter valued at about $28,000. Jones Financial Companies Lllp increased its stake in shares of uniQure by 509.0% in the third quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company's stock worth $33,000 after purchasing an additional 509 shares in the last quarter. Knott David M Jr bought a new stake in shares of uniQure in the third quarter valued at approximately $117,000. Westfield Capital Management Co. LP bought a new stake in shares of uniQure in the third quarter valued at approximately $223,000. Finally, Ballentine Partners LLC purchased a new stake in shares of uniQure during the 3rd quarter valued at approximately $301,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

Insider Transactions at uniQure

In related news, insider Jeannette Potts sold 3,412 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $30,912.72. Following the sale, the insider owned 138,483 shares in the company, valued at approximately $1,254,655.98. This trade represents a 2.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Robert Gut sold 25,613 shares of uniQure stock in a transaction on Monday, January 12th. The shares were sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director directly owned 32,342 shares of the company's stock, valued at $796,260.04. This represents a 44.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 81,399 shares of company stock valued at $1,527,645. Corporate insiders own 4.79% of the company's stock.

uniQure Price Performance

Shares of NASDAQ:QURE opened at $17.99 on Tuesday. The company has a 50 day moving average of $21.90 and a 200 day moving average of $29.64. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.25. The stock has a market cap of $1.12 billion, a P/E ratio of -5.21 and a beta of 0.73. uniQure N.V. has a 12 month low of $7.76 and a 12 month high of $71.50.

uniQure (NASDAQ:QURE - Get Free Report) last posted its earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The business had revenue of $5.57 million for the quarter, compared to analysts' expectations of $4.84 million. As a group, sell-side analysts forecast that uniQure N.V. will post -3.75 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wolfe Research assumed coverage on shares of uniQure in a report on Monday, February 23rd. They issued a "peer perform" rating for the company. Wall Street Zen downgraded uniQure from a "hold" rating to a "sell" rating in a research report on Sunday, January 11th. The Goldman Sachs Group cut their price target on uniQure from $37.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday, March 3rd. Chardan Capital lifted their price target on uniQure from $16.00 to $31.00 and gave the company a "buy" rating in a research report on Monday. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $9.00 price objective (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Nine analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $41.33.

Key Headlines Impacting uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Analyst upgrades and price‑target increases lifting sentiment — Wells Fargo upgraded QURE to "overweight" with a $60 PT and Chardan boosted its PT to $31 with a buy rating; RBC moved to "outperform" with a $35 PT. These calls drove constructive re‑ratings and buy-side interest. Wells Fargo Upgrade Chardan PT Raise
• Positive Sentiment: Regulatory leadership change in the FDA (CBER director Vinay Prasad’s announced exit) is being interpreted by the market as easing near‑term regulatory risk for gene‑therapy programs, prompting a sector rally that lifted uniQure shares. Blockonomi: Stock Soars on FDA Exit Benzinga: Biotech Reaction
• Neutral Sentiment: Analyst and media coverage is spotlighting uniQure ahead of key AMT‑130 catalysts; these pieces increase visibility but do not change fundamentals absent clinical or regulatory news. 24/7 Wall St. Analyst Interest
• Negative Sentiment: Multiple law firms have filed or publicized investor notices seeking lead plaintiffs for a securities class action covering Sept. 24–Oct. 31, 2025 (claims tied to AMT‑130 disclosures). The proliferation of filings (Faruqi, Hagens Berman, Levi & Korsinsky, Portnoy, Rosen) creates legal and disclosure risk and could impose costs or settlement pressure. Faruqi & Faruqi Notice Hagens Berman Alert Levi & Korsinsky Notice Portnoy Law Firm Rosen Law Firm Notice
• Negative Sentiment: Coverage highlighting "confusion" and shifting narratives around uniQure’s disputes with the FDA over AMT‑130 suggests ongoing regulatory uncertainty that could weigh on valuation until resolved. The Pharma Letter: Confusion Grows Yahoo Finance: Shifting Narrative

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure's pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington's disease, and Parkinson's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.